Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
Description
                A subset of patients experiences persistent fatigue symptoms after COVID-19, and patients may develop long COVID, which is characterized by lasting systemic symptoms. No treatments for this condition have been validated and are urgently warranted. In
          